bioAffinity Launches Major Lung Cancer Detection Study

bioAffinity Technologies, Inc. ( (BIAF) ) has shared an announcement.

On March 10, 2026, bioAffinity Technologies announced the start of a 2,000-patient, large-scale longitudinal clinical study to evaluate the clinical performance of its CyPath® Lung technology for early detection of lung cancer in high-risk individuals with indeterminate nodules. The study will use FlowPath Lung, an investigational version of the same sputum-based flow cytometry assay, to follow patients for up to 24 months across as many as 20 sites, including a dozen VA medical centers and two major military hospitals.

Supported and partially funded by the John P. Murtha Cancer Center Research Program at the Uniformed Services University, the trial is designed to generate robust real-world data across diverse populations, including military personnel and veterans. The company views this study as a key milestone that could help position CyPath® Lung as part of the standard of care, potentially expanding physician adoption of its noninvasive test to bridge the gap between watchful waiting and more invasive diagnostic procedures in lung cancer workups.

The most recent analyst rating on (BIAF) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.

Spark’s Take on BIAF Stock

According to Spark, TipRanks’ AI Analyst, BIAF is a Neutral.

The score is held down primarily by weak financial performance (declining revenue, large losses, very negative ROE, and negative operating cash flow). Technicals also lean bearish (below moving averages and negative MACD). Positive corporate updates (CAP accreditation and CyPath® Lung traction) and the lack of a meaningful P/E due to losses provide only limited offset.

To see Spark’s full report on BIAF stock, click here.

More about bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc. is a biotechnology company focused on non-invasive diagnostics and early cancer detection, particularly for lung disease. Its first product, CyPath® Lung, is a laboratory developed sputum-based test that uses flow cytometry and artificial intelligence to detect early-stage lung cancer in high-risk patients.

CyPath® Lung has demonstrated high clinical performance in earlier studies, showing 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients with small indeterminate pulmonary nodules. The test is marketed through the company’s subsidiary, Precision Pathology Laboratory Services, and is aimed at improving diagnosis and risk stratification in lung cancer screening populations.

Average Trading Volume: 148,289

Technical Sentiment Signal: Sell

Current Market Cap: $4.77M

Learn more about BIAF stock on TipRanks’ Stock Analysis page.